Annual Financials for Indaptus Therapeutics Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | - | - | - | |
Sales Growth |
- | - | - | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
829,000 | 859,000 | 854,000 | 852 | 1,403 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
829,000 | 859,000 | 854,000 | 852 | 1,403 | |
Depreciation |
829,000 | 859,000 | 854,000 | 852 | 1,403 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | 3.62% | -0.58% | -99.90% | 64.67% | |
Gross Income |
(829,000) | (859,000) | (854,000) | (852) | (1,403) | |
Gross Income Growth |
- | -3.62% | 0.58% | 99.90% | -64.67% | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
28.61M | 42.47M | 34.09M | 3.6M | 7.73M | |
Research & Development |
24.3M | 35.4M | 26.66M | 2.66M | 2.52M | |
Other SG&A |
4.32M | 7.07M | 7.43M | - | - | |
SGA Growth |
- | 48.44% | -19.72% | -89.44% | 114.75% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
(220,000) | 194,000 | 13.65M | - | - | |
EBIT after Unusual Expense |
220,000 | (43.52M) | (48.6M) | - | - | |
Non Operating Income/Expense |
70,000 | (747,000) | 1.32M | 15,110 | 17,720 | |
Non-Operating Interest Income |
286,000 | 852,000 | 330,000 | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
17,000 | 23,000 | 15,000 | - | - | |
Interest Expense Growth |
- | 35.29% | -34.78% | - | - | |
Gross Interest Expense |
17,000 | 23,000 | 15,000 | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(28.88M) | (43.44M) | (46.96M) | (3.58M) | (7.71M) | |
Pretax Income Growth |
- | -50.42% | -8.11% | 92.37% | -115.15% | |
Pretax Margin |
- | - | - | - | - | NA |
Income Tax |
29,000 | 103,000 | 638,000 | - | - | |
Income Tax - Current Domestic |
- | - | 638,000 | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(28.91M) | (43.54M) | (47.6M) | (3.58M) | (7.71M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(28.91M) | (43.54M) | (47.6M) | (3.58M) | (7.71M) | |
Net Income Growth |
- | -50.62% | -9.31% | 92.47% | -115.15% | |
Net Margin Growth |
- | - | - | - | - | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(28.91M) | (43.54M) | (47.6M) | (3.58M) | (7.71M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(28.91M) | (43.54M) | (47.6M) | (3.58M) | (7.71M) | |
EPS (Basic) |
(130.96) | (111.67) | (112.74) | (7.37) | (1.89) | |
EPS (Basic) Growth |
- | 14.73% | -0.96% | 93.46% | 74.43% | |
Basic Shares Outstanding |
220,750 | 389,913 | 422,200 | 486,168 | 4.09M | |
EPS (Diluted) |
(130.96) | (111.67) | (112.74) | (7.37) | (1.89) | |
EPS (Diluted) Growth |
- | 14.73% | -0.96% | 93.46% | 74.43% | |
Diluted Shares Outstanding |
220,750 | 389,913 | 422,200 | 486,168 | 4.09M | |
EBITDA |
(28.61M) | (42.47M) | (34.09M) | (3.6M) | (7.73M) | |
EBITDA Growth |
- | -48.44% | 19.72% | 89.44% | -114.75% | |
EBITDA Margin |
- | - | - | - | - | NA |